The Most Impactful FDA Drug Approvals of 2024: A Transformative Year for Biopharma As we approach the end of 2024, the biopharmaceutical industry has seen a wave of innovation, marked by FDA approvals that promise to reshape treatment paradigms across various therapeutic areas. From breakthrough therapies for genetic disorders to novel approaches in oncology and chronic diseases, 2024 has been a pivotal year. Here’s a comprehensive look at Read more
2024’s Top 12 Clinical Trials: Transforming the Future of Medicine These groundbreaking trials showcase key trends driving clinical research and innovation in 2024: Precision Medicine: Therapies like mRNA-4157 (melanoma) and atezolizumab (thyroid cancer) highlight how targeted treatments improve survival and transform care. Immunotherapy: Innovations such as nivolumab (Hodgkin lymphoma) and toripalimab (lung cancer) redefine oncology, offering enhanced survival and treatment options. Metabolic Health: Breakthroughs like Read more
Reflections on ASH 2024: Transformative Breakthroughs in Hematology-Oncology The 66th American Society of Hematology (ASH) Annual Meeting, held from December 7-10 in San Diego and online, delivered on its promise of showcasing groundbreaking advancements in hematology and oncology. Cromos Pharma’s CEO Vlad Bogin attended this event and prepared his takeaways on the most exciting and impactful insights shared at the conference. ASH 2024 Read more
Exploring Türkiye’s Edge in Clinical Research: Insights into Hospital Systems and Regulatory Framework Featuring Seniz Sagol, Türkiye Country Head at Cromos Pharma The clinical research landscape in Türkiye is undergoing a dynamic transformation, offering a unique combination of opportunities and challenges for sponsors and stakeholders alike. With its well-established healthcare infrastructure, vast patient population, and a growing commitment to aligning with international standards, Türkiye is becoming an increasingly Read more
